| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $478.41M | ||||
| Company | Location | Date | Amt. (M) | Details |
| Adnexus Therapeutics | Waltham, Mass. | 8/9 | $15.5 | Adnexus raised $15.5M in a Series C led by HBM BioVentures Ltd.; it included investments from Atlas Venture, Flagship Ventures, Polaris Venture Partners and Venrock |
| Aegera Therapeutics Inc. | Montreal | 8/8 | ND | Aegera closed its Series C financing, which raised $14M in equity and up to $7M in venture debt last November; the combination of Series C equity, debt and funding gained through an acquisition was as much as $25M |
| Agendia BV | Amsterdam, the Netherlands |
8/28 | €25 ($34) |
Agendia raised $34M in a fourth financing round; investors were ING, Van Herk Biotech BV, Gilde Healthcare Partners BV and Global Life Science Ventures |
| AM-Pharma BV | Bunnik, the Netherlands | 8/6 | €2.5 ($3.4) | AM-Pharma raised $3.4M from existing investors Forbion Capital Partners and Inventages Venture Capital in the first tranche of a Series C financing |
| Aquapharm BioDiscovery Ltd. | London | 8/15** | £4 ($8) | Aquapharm raised $8M in its first round led by Aescap Ventures and the venture arm of Tate and Lyle plc; other investors were regional development agencies and Nesta Investments |
| Azur Pharma Ltd. | Dublin, Ireland | 8/7 | $48 | Azur completed a $48M private placement arranged through Davy Corporate Finance Ltd. |
| BioMarck Pharmaceuticals Ltd. | Research TrianglePark, N.C. | 8/8 | $4 | BioMarck raised $4M in a private financing |
|
Celator Pharmaceuticals |
Princeton, N.J. | 8/2 | $10 | Celator closed a $10M private equity round, representing a follow-on investment from principal investors Domain Associates LLC, Quaker Bio-Ventures, TL Ventures, Ventures West Management Inc., GrowthWorks Capital Ltd., the Business Development Bank of Canada and Hearthstone Investment Ltd. |
| Celltran Ltd. | Sheffield, UK | 8/22** | £1 ($1.98) | Celltran raised $1.98M in a round led by Yorkshire Fund Managers; other investors were South Yorkshire Investment Fund, Innogenetics NV, Biofusion plc, White Rose Technology Seed-corn Fund and PUK Ventures |
| Celsense Inc., Glucose Sensing Technologies LLC and Falcon Genomics Inc. | Pittsburgh | 8/14 | $0.35 | The companies raised a total of $350,000 through the Pittsburgh Life Sciences Greenhouse |
| Edison Pharmaceuticals Inc. | San Jose, Calif. | 8/2 | $4.25 | Edison closed a $4.25M Series B preferred stock offering led by Carl Berg, of Berg & Berg Enterprises LLC; new investors included John W. Marriott III, president and CEO of JWM LP, and JWM Family Enterprises |
| EKR Therapeutics Inc. | Cedar Knolls, N.J. | 8/15 | $13 | EKR raised $13M in a Series C round led by Quaker BioVentures; other investors are Merrill Lynch Capital Healthcare Finance Group, Garden State Life Sciences Venture Fund, NewSpring Capital and ESP Equity Partners |
| Inotek Pharmaceuticals Corp. | Beverly, Mass. | 8/24 | $19.3 | Inotek raised $19.3M in a Series C round, which included investments from Hercules Technology Growth Capital, Meditor Capital Management and Mitsubishi UFJ Capital, as well as Care Capital LLC, La Caisse de Depot et placement du Quebec, MedImmune Ventures, Pitango Venture Capital and Rho Ventures |
| IntelliPharma-Ceutics Ltd. | Toronto | 8/2 | ND | Par Pharmaceutical Cos. Inc. made a significant equity investment in the company, acquiring a 4.2% interest in the company |
| KineMed Inc. | Emeryville, Calif. | 8/3 | $15 | KineMed completed a $15M convertible note offering led by a direct investment from Stanford Financial Group and joined by existing investors from previous financing rounds; Ledge-mont Capital served as placement agent |
| Molecular Partners AG | Schlieren, Switzerland | 8/14 | CHF18.5 ($15.3) | Molecular Partners raised $15.3M in a Series A round led by Index Ventures; other participants were BB Biotech Ventures, Johnson & Johnson Development Corp. and Endeavour Vision |
| Nereus Pharmaceuticals Inc. | San Diego | 8/9 | $45 | Nereus raised $45M in a Series D-2 financing round led by BankInvest Biomedical Venture; other investors were Roche Venture Fund, Astellas Venture Management, Boston Life Science Venture Corp., Taiwan Global Biofund and Eminent Venture Capital Corp. |
| NeurAxon Inc. | Waltham, Mass. | 8/20 | $32 | NeurAxon raised $32M in a Series B round led by Delphi Ventures and OrbiMed Advisors LLC; other investors were BDC Venture Capital, Genesys Capital Partners, H.I.G. Ventures, Neuro-Ventures Fund, Ventures West Capital Ltd. and CEO Lawrence Bloch |
| Neuromed Pharmaceuticals Inc. | Vancouver, British Columbia | 8/21 | $53.3 | Neuromed closed a $53.3M Series E financing; investors were MPM Capital, James Richardson & Sons Ltd., Neuro Discovery LP, GrowthWorks Capital, BDC Venture Capital, Canadian Medical Discoveries Fund Inc. and the Royal Bank of Canada |
| Novacta Biosystems Ltd. | Welwyn Garden City, UK | 8/3 | €0.6($0.827) | Novacta completed an investment round from new investors, including Esperante, and existing shareholders Westgate Hall, GEIF Ventures and Oxford Technology 4 VCT |
| OncoVista Inc. | San Antonio | 8/30 | $6.8 | OncoVista raised $6.8M selling 970,712 units consisting of stock and warrants; investors were Wexford Capital LLC, CAMOFI Master LDC, Bristol Investment Fund Ltd. and other institutional and qualified investors; Maxim Group LLC was exclusive placement agent for the deal |
| Ophthotech | Princeton, N.J. | 8/13 | $36 | Ophthotech raised $36M in a Series A round led by SV Life Sciences, with participation from HBM BioVentures and Novo A/S |
| Pevion Biotech AG | Bern, Switzerland | 8/10 | CHF35 ($29.3) | Pevion raised $29.3M in a Series A round led by BZ Bank AG; other participants included BB Biotech Ventures II LP, which is advised by Bellvue Asset Management AG and CC Private Equity Partners Ltd. |
| Presidio Pharmaceuticals Inc. | San Francisco | 8/29 | $26 | Presidio raised $26M in a Series B round; investors were Baker Brothers Investments, Bay City Capital, Ventures West Capital and Nexus Medical Partners, as well as Sagamore Bioventures, George Rathmann Fund and Peninsula Overview Partners |
| Proteros biostructures GmbH | Martinsried, Germany | 8/22 | €1 ($1.4) | Proteros received a $1.4M investment from BayBG Bayerische Beteiligungsgesellschaft mbH |
| Tobira Therapeutics | Princeton, N.J. | 8/2 | $31 | Tobira raised $31M in a Series A round led by Domain Associates and Frazier Healthcare Ventures; Montreux Equity Partners and Canaan Partners also participated |
| Topigen Pharmaceuticals Inc. | Montreal | 8/15 | C$26 ($24.7) |
Topigen closed a Series C round, raising $24.7M; BDC Venture Capital led the first close, with participation from Desjardins Venture Capital, Caisse de depot et placement du Quebec, 12C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR, as well as MMV Financial Inc. and NovaQuest |
| Notes: | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| ND = Not disclosed. | ||||